Objectives: To describe patterns of recurrence and postrecurrence survival in a large cohort of accurately staged patients with Dukes' A-C colorectal cancer. Background: Recurrence remains a frequent cause of mortality after the treatment of colorectal cancer with curative intent. Understanding the likelihood and site of recurrence informs adjuvant treatment and follow-up. Methods: Retrospective cohort analysis of data from the FACS (follow-up after colorectal cancer surgery) trial after a median 4.4 years of follow-up; postrecurrence survival was calculated using the Kaplan-Meier method. Results: Complete data were available for 94% of patients; 189 (17%) patients had experienced recurrence. Incidence of recurrence varied according to the site of the primary (right colon: 51/379, 14%; left colon: 68/421, 16%; rectum: 70/332, 21%; P ¼ 0.023) and initial stage (Dukes' A: 26/249, 10%; Dukes' B: 81/537, 15%; Dukes' C: 82/346, 24%; P < 0.0001). Pulmonary recurrence was most frequently associated with rectal tumors, and multisite/ other recurrence with right-sided colonic tumors. Recurrences from lowerstage tumors were more likely to be treatable with curative intent (Dukes' A: 13/26, 50%; Dukes' B: 32/81, 40%; Dukes' C: 20/82, 24%; P ¼ 0.03). Those with rectal tumors benefited most from follow-up (proportion with treatable recurrence: rectum 30/332, 9%; left colon 23/421, 6%; right colon 12/379, 3%; P ¼ 0.003). Both initial stage (log rank P ¼ 0.005) and site of primary (log rank P ¼ 0.01) influenced postrecurrence survival. Conclusions: The likelihood and site of recurrence, and survival, are influenced by the site and stage of the primary tumor. Those with rectal cancers benefited most from follow-up. ISRCTN 41458548
R ecurrence remains a frequent cause of mortality after the surgical treatment of colorectal cancer with curative intent. Understanding both the likelihood and site of recurrence is important for planning optimal adjuvant treatment and follow-up. For example, rectal cancer has a well-established tendency to recur locally; however, the combination of total mesorectal excision and optimal chemoradiotherapy has reduced rates to less than 10% in modern series. [1] [2] [3] [4] Existing evidence on the pattern of recurrence after curative resection of colorectal cancer is limited to retrospective audits, [5] [6] [7] and data from high-quality randomized controlled trials are lacking. Trials of adjuvant therapies for colon and rectal cancer reveal certain information on patterns of recurrence, but these are by definition limited to more advanced-stage cancers requiring such treatments. 8 Surgical resection of both metastatic and locally recurrent lesions is now widely practiced with a good proportion of patients enjoying long-term survival. [9] [10] [11] These meta-analyses report prognostic features for survival after recurrence; however, they include patients with both synchronous and nonsynchronous presentations and the disease biology may be different. Furthermore, the prognostic factors identified typically relate to observations at the time advanced disease is identified, such as number and size of metastatic lesions, and carcinoembryonic (CEA) antigen level, 10, 11 with less emphasis placed on characteristics of the primary tumor.
The FACS (follow-up after colorectal cancer surgery) trial data, therefore, provide an important opportunity to refine our understanding of the prognostic significance of initial site and stage on the frequency and site of recurrence. One of the key findings of the trial was the low overall incidence of recurrence, thought to be due to the rigor of the investigative procedures undertaken to ensure that no residual disease was present at trial entry. 12 As such, this affords a unique population of patients with colorectal cancer surgically treated with curative intent, both accurately staged and prospectively followed up, in which to analyze patterns of disease recurrence and factors influencing postrecurrence survival.
METHODS
A total of 1202 patients were recruited to the UK FACS trial between January 2003 and August 2009; this analysis is restricted to 1132 patients (94.2%) for whom complete detailed data are available on initial stage and site of recurrence. The cutoff date for this analysis is August 31, 2012, by which time all patients had reached a minimum of 3 years of follow-up, with a median follow-up of 4.4 years since randomization.
All FACS trial participants had undergone curative treatment of primary colorectal cancer, Dukes' A-C staging (Tumor node metastasis stages I-III), with microscopically clear margins. All were disease-free on colonic imaging, with no evidence of metastatic disease [computed tomographic (CT) scan: chest abdomen pelvis AE magnetic resonance image: liver] and with a postoperative blood CEA 10 mg/mL or less. For those receiving adjuvant therapy, the CEA was measured at completion of treatment and a CT performed. Patients were randomized using a factorial 2 Â 2 randomized design from 41 centers in the United Kingdom to 6 to 12 monthly CT or minimum follow-up and to 3 to 6 monthly CEA testing or minimum follow-up; details of the design, conduct, and results of this clinical trial are available in the original publication. 12 This retrospective cohort analysis aggregates data from all 4 trial arms.
Information on deaths was collected by flagging each participant at the Office for National Statistics central registry; as all patients who withdrew from the study gave permission for continuation of flagging, the mortality follow-up is complete except for 1 patient who has emigrated. Cause of death was abstracted from death certificates; in some cases, clinical records were consulted to investigate further the role of colorectal cancer as an important contributory cause of death. Data on treatment of recurrence and treatment intent were abstracted from the hospital records by the local National Institute for Health Research cancer network nurse and collated by the data manager in Oxford; these data were reviewed independently by the chief clinical investigators (blind to allocation group) to check for consistency and, where necessary, further information was sought from the relevant clinical teams to resolve any clinical ambiguity. The final decision on treatment intent was made at a review meeting with independent clinical input.
Categorical variables are presented as frequencies (percentages) and the x 2 test used for comparisons. The Kaplan-Meier method was used for survival analyses and the log-rank test was used to compare survival between groups; P value of less than 0.05 was considered significant. Tables were produced using SPSS statistical software version 22 (IBM Corp, NY), and survival analyses were carried out using the ''survival'' package in R (R Development Core Team, 2014).
RESULTS

Incidence of Recurrence
Within the median follow-up period of 4.4 years (interquartile range: 3.1-5.0 years), 189 participants (17%) developed recurrence. The mean age of participants with recurrence was 67.8 years and 63% were male ( Table 1 ). The incidence of recurrence varied according to the site of the original tumor. Recurrence was detected in 14% (51/379) of participants with a right-sided colonic primary tumor, 16% (68/421) with a left-sided colonic primary tumor, and 21% (70/332) with a primary tumor in the rectum (P ¼ 0.023) ( Table 2 ). Predictably, recurrence was more frequent in those with a more advanced stage primary tumor; 10% of participants with a Dukes' A primary tumor developed recurrence (26/249) compared with 15% (81/537) with a Dukes' B and 24% (82/346) with a Dukes' C primary tumor (P < 0.0001) ( Table 2 ). 
Site of Recurrence
Of the 189 participants with recurrence, single site recurrence in the liver, lung, or locally was present in 124 (liver ¼ 50, lung ¼ 33, and locoregional ¼ 41), with the remainder having recurrence at other or multiple sites. Overall, the liver was the most frequent site of recurrence, with 42% (79/189) of all recurrences involving the liver. Interestingly, the distribution of recurrent disease varied according to the location of the primary tumor. Recurrence involving just the lung was most frequently associated with primary tumors in the rectum (right colon ¼ 3/33, 9%; left colon ¼ 8/33, 24%; rectum ¼ 22/33, 67%; P < 0.0001). In addition, recurrence at sites other than the lung, liver, or locoregionally, or at more than one of those sites was most likely to be experienced by those with right colonic primary tumors (right colon ¼ 25/65, 38%; left colon ¼ 23/65, 35%; rectum ¼ 17/65, 26%; P ¼ 0.018). Site of recurrence was also influenced by the stage of primary tumor; both locoregional recurrence and recurrence at multiple/other sites were most frequently associated with higherstage primary tumors (see Table 2 ).
Incidence of Recurrent Disease Treatable Surgically With Curative Intent
Of the 189 participants with recurrence, a total of 65 (34%) underwent treatment with curative intent (Table 3 ). Those participants with recurrence and a lower-stage original tumor were more likely to undergo resection (Dukes' A 13/26, 50%; Dukes' B 32/81, 40%; Dukes' C 20/82, 24%; P ¼ 0.08). Although there was no significant difference in the likelihood of recurrent disease being amenable to curative resection according to the site of original tumor, a trend was apparent (right colon: 12/51, 24%; left colon: 23/68, 34%; rectum: 30/70, 43%; P ¼ 0.086).
Benefit of Follow-up
Although recurrent disease was more likely to be resectable in those with a lower-stage primary tumor, the proportion of participants with recurrence surgically treated with curative intent taken as a proportion of the whole trial cohort was similar for each Dukes' stage (A: 13/249, 5%; B: 32/537, 6%; C: 20/346, 6%; P ¼ 0.80). As such, a key finding of the FACS trial was that the benefit of follow-up is independent of stage-that is, while recurrence is less frequent in those with Dukes' A primary tumors, it is more likely to be treatable. 12 By contrast, the benefit of follow-up did vary according to the site of the primary tumor. Those participants with a rectal primary tumor were more likely to have a treatable recurrence detected during the follow-up period (right colon: 12/379, 3%; left colon: 23/421, 6%; rectum: 30/332, 9%; P ¼ 0.003).
Survival Postrecurrence
Of the 189 patients diagnosed with recurrent disease, 113 (60%, 106 specifically from recurrence and 7 from other causes) died during the follow-up period. Survival postrecurrence differed according to both the site (log rank P ¼ 0.01) and stage (log-rank P ¼ 0.005) of the primary tumor (Figs. 1A, B ). When just those participants with recurrence from a Dukes' C primary tumor are considered, there is no difference in postrecurrence survival according to site of the original tumor (figure online only). However, for those participants with a Dukes' B primary tumor, the site of original tumor seems to influence postrecurrence survival (log-rank P ¼ 0.002-figure online only). There were insufficient numbers to make comparisons among those with a Dukes' A primary tumor.
Survival postrecurrence also differed according to the site of recurrent disease. Those with multisite recurrence or metastatic recurrence at other sites had an inferior survival to those with single site recurrence in the liver, lung, or locoregionally (Fig. 1C , log rank P < 0.0001), consistent with the high proportion of patients with these single site recurrences undergoing surgical treatment with curative intent (liver only 30/50, 60%; lung only 13/33, 40%; locoregionally only 16/41, 40%; multisite/other recurrence 6/65, 9%).
For those amenable to treatment with curative intent, around three-quarters (44/65, 74%) were still alive at the end of the followup period. Neither the site nor the stage of the primary tumor influenced the survival of those with recurrent disease treated with curative intent, although there was a trend toward worse survival in those with a higher-stage primary tumor (Fig. 2) .
DISCUSSION
This is the first study to report patterns of recurrence and postrecurrence survival in patients with Dukes' A-C colorectal cancer treated with curative intent in a prospectively followed up, large cohort of patients. As stated in the introduction, the rigor of investigative procedures undertaken to ensure that patients were free of disease before recruitment provided an accurately staged population in which to assess the true incidence of disease recurrence.
As might be expected, the results confirm that recurrent disease is most frequent in those with a more advanced stage primary tumor at original diagnosis, even when the staging to identify postoperative residual disease is done meticulously. They also largely confirm the pattern of recurrence reported by other studies [6] [7] [8] ; although the liver is the most frequent site of recurrence for both colonic and rectal tumors, there is a preponderance of solitary pulmonary metastasis in those with primary tumors in the rectum. This supports the contention that hematogenous spread via the iliac veins results in a higher incidence of lung metastases from rectal cancer. 13, 14 By contrast, locoregional recurrence of rectal tumors was relatively uncommon and certainly no more frequent than colonic tumors. This is consistent with the modern use of surgical techniques to ensure a complete excision of the mesorectum selectively combined with the use of chemoradiotherapy that has dramatically reduced the rates of locoregional recurrence from rectal cancer. [1] [2] [3] [4] A novel finding from this analysis is the suggestion that multisite recurrence is more common with right-sided colonic primary tumors. Furthermore, a recurrent right-sided colonic primary tumor is less likely to be resectable than left-sided tumors. Whereas a key finding of the FACS trial was that the benefit of follow-up was independent of stage, it is not independent of tumor site-almost 3 times as many participants with a rectal primary tumor had recurrent disease detected that was amenable to treatment with curative intent compared with those with a right-sided colonic tumor.
Differences in the clinical presentation and tumor biology between right-and left-sided colonic cancers have long been reported, [15] [16] [17] [18] and there is now evidence to suggest that different genetic alterations dominate the pathway to relapse between right and left-sided colonic tumors. 19 Traditionally, right-sided tumors are believed to present later and be associated with advanced-stage disease at presentation, 20 but worse prognosis for right-sided colonic tumors has only been consistently observed in stage III cancers. 16, 21 Our data show that patients with a right-sided tumor are disadvantaged in terms of postrecurrence survival.
The observation that the Dukes' stage of the primary tumor influenced survival after the development of recurrent disease is in agreement with an analysis of patients with stage II and III diseases who had participated in trials of adjuvant chemotherapy. 22 In that analysis, stage II patients had a longer survival after tumor recurrence than stage III patients. It may be that a higher-stage tumor at original diagnosis does not simply reflect a later stage in the developmental pathway of colorectal cancer but rather a more aggressive tumor type, the prognostic implications of which remain if recurrence occurs.
The site of cancer recurrence also influenced survival postdiagnosis of recurrent disease. It is perhaps unsurprising that those with multisite recurrence had an inferior survival to those with recurrence at the single sites of liver, lung, or locoregionally, particularly when considering the low proportion of these participants who were surgically treatable with curative intent. It is, however, noteworthy that the survival of those with locoregional only recurrence was comparable with that of liver only and lung only recurrence. This supports the current approach of aggressive surgical management of these patients when possible.
Finally, the recently published guidelines on follow-up endorsed by the American Society of Clinical Oncology noted that there was insufficient evidence to make any clear recommendations for patients with resected stage I disease. 23 The FACS trial now provides us with unequivocal evidence for undertaking surveillance with either CEA measurements or CT in patients with Dukes' A-C colorectal cancer. 12 Although the benefit of follow-up does differ according to the site of primary colorectal cancer, we would still recommend undertaking equivalent surveillance strategies in all patients, accepting that there is simply different disease biology at play. It will, however, provide valuable information to clinicians counseling individual patients about the relative benefits to them participating in a follow-up strategy.
CONCLUSIONS
The FACS cohort demonstrates that characteristics of the primary colorectal tumor, specifically site and stage, influence not only the likelihood of recurrence but also the distribution of recurrent disease and postrecurrence survival. The influence of stage on outcome even postrecurrence suggests that the stages of primary colorectal cancer represent different disease biology rather than simply points in the timeline of disease progression.
